Experience of treatment of a patient with non-small cell lung cancer with met exon 14 skipping
Personalized therapy is starting to play an increasing role in modern approaches to the treatment of oncological diseases. The previously existing uniform standard for each malignant disease is expanded with new options and treatment possibilities, depending on each specific clinical situation. That...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2021-08-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/6267 |
| _version_ | 1797841283650158592 |
|---|---|
| author | M. O. Mandrina V. V. Breder M. V. Ivanov A. A. Lebedeva V. V. Gorbatsevich K. K. Laktionov P. V. Kononets |
| author_facet | M. O. Mandrina V. V. Breder M. V. Ivanov A. A. Lebedeva V. V. Gorbatsevich K. K. Laktionov P. V. Kononets |
| author_sort | M. O. Mandrina |
| collection | DOAJ |
| description | Personalized therapy is starting to play an increasing role in modern approaches to the treatment of oncological diseases. The previously existing uniform standard for each malignant disease is expanded with new options and treatment possibilities, depending on each specific clinical situation. That increases the effectiveness of therapy and helps to control the disease. A separate niche in the individual approach to anti-tumor treatment is occupied by targeted therapy of malignancies. There are a lot of mutations that can lead to the emergence of malignant neoplasms. So of all that multitude of choices the individual approach to a patient helps to select the mutations that are most likely to be found in a given patient. The research in the area of the c-MET mutation has allowed it to occupy its niche as a therapeutic target. The identification of this mutation is not included in the routine set of analyses performed for a patient with diagnosed lung adenocarcinoma. But expanding the panel of molecular testing would increase the detectability of this mutation and, as a result, improve the quality of treatment for this category of patients. This clinical case describes the experience of treatment of an elderly patient with lung adenocarcinoma, in whose tumor tissue a MET mutation was detected. |
| first_indexed | 2024-04-09T16:28:29Z |
| format | Article |
| id | doaj.art-57964881696b4a4fb74301f5336982f7 |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:28:29Z |
| publishDate | 2021-08-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-57964881696b4a4fb74301f5336982f72023-04-23T06:57:12ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902021-08-010915415910.21518/2079-701X-2021-9-154-1595662Experience of treatment of a patient with non-small cell lung cancer with met exon 14 skippingM. O. Mandrina0V. V. Breder1M. V. Ivanov2A. A. Lebedeva3V. V. Gorbatsevich4K. K. Laktionov5P. V. Kononets6Blokhin National Medical Research Centre of OncologyBlokhin National Medical Research Centre of OncologyMoscow Institute of Physics and Technology (National Research University)Sechenov First Moscow State Medical University (Sechenov University)Blokhin National Medical Research Centre of OncologyBlokhin National Medical Research Centre of OncologyBlokhin National Medical Research Centre of OncologyPersonalized therapy is starting to play an increasing role in modern approaches to the treatment of oncological diseases. The previously existing uniform standard for each malignant disease is expanded with new options and treatment possibilities, depending on each specific clinical situation. That increases the effectiveness of therapy and helps to control the disease. A separate niche in the individual approach to anti-tumor treatment is occupied by targeted therapy of malignancies. There are a lot of mutations that can lead to the emergence of malignant neoplasms. So of all that multitude of choices the individual approach to a patient helps to select the mutations that are most likely to be found in a given patient. The research in the area of the c-MET mutation has allowed it to occupy its niche as a therapeutic target. The identification of this mutation is not included in the routine set of analyses performed for a patient with diagnosed lung adenocarcinoma. But expanding the panel of molecular testing would increase the detectability of this mutation and, as a result, improve the quality of treatment for this category of patients. This clinical case describes the experience of treatment of an elderly patient with lung adenocarcinoma, in whose tumor tissue a MET mutation was detected.https://www.med-sovet.pro/jour/article/view/6267met mutationpd-l1immunotherapynsclccrizotinib |
| spellingShingle | M. O. Mandrina V. V. Breder M. V. Ivanov A. A. Lebedeva V. V. Gorbatsevich K. K. Laktionov P. V. Kononets Experience of treatment of a patient with non-small cell lung cancer with met exon 14 skipping Медицинский совет met mutation pd-l1 immunotherapy nsclc crizotinib |
| title | Experience of treatment of a patient with non-small cell lung cancer with met exon 14 skipping |
| title_full | Experience of treatment of a patient with non-small cell lung cancer with met exon 14 skipping |
| title_fullStr | Experience of treatment of a patient with non-small cell lung cancer with met exon 14 skipping |
| title_full_unstemmed | Experience of treatment of a patient with non-small cell lung cancer with met exon 14 skipping |
| title_short | Experience of treatment of a patient with non-small cell lung cancer with met exon 14 skipping |
| title_sort | experience of treatment of a patient with non small cell lung cancer with met exon 14 skipping |
| topic | met mutation pd-l1 immunotherapy nsclc crizotinib |
| url | https://www.med-sovet.pro/jour/article/view/6267 |
| work_keys_str_mv | AT momandrina experienceoftreatmentofapatientwithnonsmallcelllungcancerwithmetexon14skipping AT vvbreder experienceoftreatmentofapatientwithnonsmallcelllungcancerwithmetexon14skipping AT mvivanov experienceoftreatmentofapatientwithnonsmallcelllungcancerwithmetexon14skipping AT aalebedeva experienceoftreatmentofapatientwithnonsmallcelllungcancerwithmetexon14skipping AT vvgorbatsevich experienceoftreatmentofapatientwithnonsmallcelllungcancerwithmetexon14skipping AT kklaktionov experienceoftreatmentofapatientwithnonsmallcelllungcancerwithmetexon14skipping AT pvkononets experienceoftreatmentofapatientwithnonsmallcelllungcancerwithmetexon14skipping |